此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effects of Magnesium and Spinning Training on Echocardiographic, Inflammatory, and Aerobic Outcomes

2026年6月17日 更新者:Hikmet Kocaman、Karamanoğlu Mehmetbey University

Effects of Magnesium Supplementation and Spinning Training on Cardiac Function, Oxidative Stress, Inflammation, and Aerobic Capacity

Regular aerobic exercise may improve cardiorespiratory fitness while modulating systemic inflammation and oxidative stress. Spinning, as a structured indoor cycling modality, provides a practical aerobic exercise model with adjustable intensity and duration, but its effects on redox balance, inflammatory status, aerobic capacity, and cardiac functional parameters may vary according to individual recovery and nutritional status. Magnesium is an essential micronutrient involved in energy metabolism, muscle contraction-relaxation, ion regulation, and inflammatory and oxidative pathways; therefore, magnesium use may be relevant to exercise adaptation and recovery.

This study aims to evaluate the associations of magnesium use and spinning training with oxidative stress, inflammation, aerobic capacity, and cardiac parameters. In this context, biochemical markers related to oxidative/antioxidant status and inflammation, aerobic performance indicators, and echocardiographic cardiac function parameters will be assessed together. The study is expected to provide real-world evidence on whether magnesium use in individuals participating in spinning training is associated with more favorable redox, inflammatory, aerobic, and cardiac profiles.

研究概览

研究类型

介入性

注册 (估计的)

48

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Karaman、土耳其(türkiye)、70100
        • Karamanoğlu Mehmetbey University, Faculty of Sport Sciences

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

是的

描述

Inclusion Criteria:

  • Self-identified male participants
  • Aged 18 to 30 years
  • Physically active individuals
  • Participants who are eligible to participate in a structured spinning training program
  • Participants with available baseline and follow-up assessments for biochemical, aerobic capacity, and cardiac function parameters

Exclusion Criteria:

  • Presence of any chronic systemic disease
  • Acute infection during the study period
  • Regular use of anti-inflammatory or antioxidant medications
  • Use of antioxidant or ergogenic supplements other than magnesium
  • Any cardiovascular, musculoskeletal, or neurological condition that may limit participation in spinning training
  • Missing baseline or follow-up outcome data

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
无干预:Control group
Participants in this arm will not receive any exercise training, magnesium supplementation, or placebo intervention during the study period. They will continue their usual daily routines and will undergo the same baseline and follow-up assessments as the intervention groups.
有源比较器:Spinning Training Group
Participants in this arm will participate in a structured spinning training program during the study period. No magnesium supplementation or placebo will be administered. Baseline and follow-up assessments will include oxidative stress, inflammatory, aerobic capacity, and cardiac function parameters.
Participants will participate in a structured spinning training program during the study period. The program will consist of supervised indoor cycling sessions performed at a planned frequency, duration, and intensity.
实验性的:Spinning + Magnesium Group
Participants in this arm will participate in a structured spinning training program and receive magnesium supplementation during the study period. Baseline and follow-up assessments will include oxidative stress, inflammatory, aerobic capacity, and cardiac function parameters.
Participants will participate in a structured spinning training program during the study period. The program will consist of supervised indoor cycling sessions performed at a planned frequency, duration, and intensity.
Participants will receive oral magnesium supplementation during the study period in addition to the structured spinning training program.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Maximal Oxygen Uptake (VO₂max)
大体时间:Baseline and 6 weeks
Maximal oxygen uptake (VO₂max, mL/kg/min) will be assessed using a graded exercise test. The change in VO₂max from baseline to 6 weeks will be evaluated.
Baseline and 6 weeks
Change in Serum Magnesium Concentration
大体时间:Baseline and 6 weeks
Serum magnesium concentration (mg/dL) will be measured using standard laboratory methods. The change in serum magnesium levels from baseline to 6 weeks will be evaluated.
Baseline and 6 weeks

次要结果测量

结果测量
措施说明
大体时间
Change in Total Antioxidant Status (TAS)
大体时间:Baseline and 6 weeks
Serum total antioxidant status (TAS, mmol Trolox equivalent/L) will be measured using commercially available assay kits. The change in TAS from baseline to 6 weeks will be evaluated.
Baseline and 6 weeks
Change in Total Oxidant Status (TOS)
大体时间:Baseline and 6 weeks
Serum total oxidant status (TOS, μmol H₂O₂ equivalent/L) will be measured using commercially available assay kits. The change in TOS from baseline to 6 weeks will be evaluated.
Baseline and 6 weeks
Change in Paraoxonase-1 Activity (PON1)
大体时间:Baseline and 6 weeks
Serum paraoxonase-1 (PON1, U/L) activity will be determined using spectrophotometric methods. The change in PON1 activity from baseline to 6 weeks will be evaluated.
Baseline and 6 weeks
Change in Arylesterase Activity (ARE)
大体时间:Baseline and 6 weeks
Serum arylesterase (ARE, kU/L) activity will be determined using spectrophotometric methods. The change in ARE activity from baseline to 6 weeks will be evaluated.
Baseline and 6 weeks
Change in High-Sensitivity C-Reactive Protein (hs-CRP)
大体时间:Baseline and 6 weeks
Serum high-sensitivity C-reactive protein (hs-CRP, mg/L) concentration will be measured using standard laboratory methods. The change in hs-CRP levels from baseline to 6 weeks will be evaluated.
Baseline and 6 weeks
Change in Interleukin-6 (IL-6)
大体时间:Baseline and 6 weeks
Serum interleukin-6 (IL-6, pg/mL) concentration will be measured using enzyme-linked immunosorbent assay methods. The change in IL-6 levels from baseline to 6 weeks will be evaluated.
Baseline and 6 weeks
Change in Tumor Necrosis Factor-Alpha (TNF-α)
大体时间:Baseline and 6 weeks
Serum tumor necrosis factor-alpha (TNF-α, pg/mL) concentration will be measured using enzyme-linked immunosorbent assay methods. The change in TNF-α levels from baseline to 6 weeks will be evaluated.
Baseline and 6 weeks
Change in Serum Potassium Concentration
大体时间:Baseline and 6 weeks
Serum potassium concentration (mmol/L) will be measured using standard biochemical methods. The change in serum potassium levels from baseline to 6 weeks will be evaluated.
Baseline and 6 weeks
Change in Serum Calcium Concentration
大体时间:Baseline and 6 weeks
Serum calcium concentration (mg/dL) will be measured using standard biochemical methods. The change in serum calcium levels from baseline to 6 weeks will be evaluated.
Baseline and 6 weeks
Change in N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP)
大体时间:Baseline and 6 weeks
Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP, pg/mL) concentration will be measured using immunoassay methods. The change in NT-proBNP levels from baseline to 6 weeks will be evaluated.
Baseline and 6 weeks
Change in Left Ventricular Ejection Fraction (LVEF)
大体时间:Baseline and 6 weeks
Left ventricular ejection fraction (LVEF, %) will be assessed by transthoracic echocardiography. The change in LVEF from baseline to 6 weeks will be evaluated.
Baseline and 6 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Şemsi Gül Yılmaz Kocaman, PhD、Karamanoğlu Mehmetbey University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月1日

初级完成 (估计的)

2026年8月15日

研究完成 (估计的)

2026年8月20日

研究注册日期

首次提交

2026年6月5日

首先提交符合 QC 标准的

2026年6月17日

首次发布 (实际的)

2026年6月23日

研究记录更新

最后更新发布 (实际的)

2026年6月23日

上次提交的符合 QC 标准的更新

2026年6月17日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他研究编号

  • 02-2026/29

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared because the dataset contains participant-level health and performance records. All results will be reported in aggregate form, and confidentiality will be maintained in accordance with applicable data protection regulations.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅